Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14,818 Mln
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
Debt to Equity
1.92
ROE
-0.04 %
ROCE
-1.45 %
Div. Yield
2.35 %
Book Value
13.65
EPS
-0.61
CFO
$19,550.00 Mln
EBITDA
$20,409.00 Mln
Net Profit
$14,393.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Baxter International (BAX)
| 1.17 | -11.12 | -7.32 | -26.98 | -26.09 | -20.09 | -2.56 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Midcap 400
| -10.33 | -5.11 | -14.75 | -2.37 | 2.66 | 13.06 | 6.19 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Baxter International (BAX)
| -24.40 | -24.15 | -40.62 | 8.48 | -2.95 | 28.40 | 2.87 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 202.72 | 56,453.62 | 33.1 | 6.76 | |
| 70.35 | 40,534.25 | 29.57 | 50.15 | |
| 429.88 | 32,954.51 | 38.15 | 57.66 | |
| 220.55 | 34,179.18 | 48.63 | 13.63 |
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and... Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. Address: One Baxter Parkway, Deerfield, IL, United States, 60015 Read more
Chairman of the Board, President & CEO
Mr. Jose E. Almeida
Executive VP, CFO & Interim Chief Accounting Officer
Mr. Joel T. Grade
Headquarters
Deerfield, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Baxter International Inc (BAX) stood at $ 25,782 Mln as on 31-Dec-24
The share price of Baxter International Inc (BAX) is $29.50 (NYSE) as of 23-Apr-2025 14:33 EDT. Baxter International Inc (BAX) has given a return of -26.09% in the last 3 years.
Baxter International Inc (BAX) has a market capitalisation of $ 14,818 Mln as on 22-Apr-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Baxter International Inc (BAX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Baxter International Inc (BAX) and enter the required number of quantities and click on buy to purchase the shares of Baxter International Inc (BAX).
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. Address: One Baxter Parkway, Deerfield, IL, United States, 60015
The CEO & director of Mr. Jose E. Almeida. is Baxter International Inc (BAX), and CFO & Sr. VP is Mr. Joel T. Grade.
There is no promoter pledging in Baxter International Inc (BAX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
5,754
|
|
|
4,171
|
|
|
3,590
|
|
|
3,274
|
| Baxter International Inc. (BAX) | Ratios |
|---|---|
|
Return on equity(%)
|
-4.06
|
|
Operating margin(%)
|
-2.7
|
|
Net Margin(%)
|
-6.91
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Baxter International Inc (BAX) was $-312 Mln.
$0.88
(
